Ten months af­ter dev­as­tat­ing fail­ure, Roche says it sees path for­ward for Hunt­ing­ton’s drug

If you had to pick 2021’s biggest drug de­vel­op­ment dis­ap­point­ment, it’d be hard to over­look the Roche-Io­n­is Hunt­ing­ton’s dis­ease tri­al.

The Phase III study rep­re­sent­ed the com­mu­ni­ty’s first ma­jor hope of hav­ing a treat­ment for the un­der­ly­ing cause of a dev­as­tat­ing dis­ease that steals most pa­tients’ cog­ni­tion in mid-life. Then, in March, Roche had to cut the tri­al short be­cause the drug seemed to some­how be mak­ing pa­tients worse. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.